Free Trial
→ A new income category is drawing serious money - here's why (From Investors Alley) (Ad)tc pixel Free ENTX Stock Alerts

Entera Bio (ENTX) Financials

Entera Bio logo
$2.50 +0.02 (+0.60%)
Closing price 03:59 PM Eastern
Extended Trading
$2.50 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Entera Bio

Annual Income Statements for Entera Bio

This table shows Entera Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -1.20 -11 -10 -11 -11 -12 -13 -8.89 -9.54 -11
Consolidated Net Income / (Loss)		 -1.20 -11 -10 -11 -11 -12 -13 -8.89 -9.54 -11
Net Income / (Loss) Continuing Operations		 -1.20 -11 -10 -11 -11 -12 -13 -8.89 -9.54 -11
Total Pre-Tax Income 		-1.20 -11 -10 -11 -11 -12 -13 -8.86 -9.53 -11
Total Operating Income		 -5.37 -11 -11 -11 -11 -12 -13 -8.89 -9.59 -12
Total Gross Profit		 0.00 0.00 0.50 0.03 0.07 0.20 0.03 0.00 0.01 0.00
Total Revenue		 0.00 0.00 0.50 0.24 0.37 0.57 0.13 0.00 0.18 0.04
Operating Revenue		 0.00 0.00 0.50 0.24 0.37 0.57 0.13 0.00 0.18 0.04
Total Cost of Revenue		 0.00 0.00 0.00 0.21 0.30 0.37 0.10 0.00 0.17 0.04
Operating Cost of Revenue		 - 0.00 0.00 0.21 0.30 0.37 0.10 0.00 0.17 0.04
Total Operating Expenses		 5.37 11 11 11 11 12 13 8.89 9.59 12
Selling, General & Admin Expense		 2.72 8.58 2.84 4.28 4.85 5.69 7.25 4.43 5.10 5.53
Research & Development Expense		 2.65 2.77 8.52 7.20 6.38 6.77 5.85 4.51 4.50 6.00
Total Other Income / (Expense), net		 4.17 0.15 0.56 0.66 -0.03 -0.03 0.08 0.03 0.06 0.09
Other Income / (Expense), net		 -0.14 -0.11 0.03 -0.08 -0.03 -0.03 0.08 0.03 0.06 0.09
Income Tax Expense		 - - 0.00 0.00 0.02 -0.06 0.14 0.03 0.01 0.00
Basic Earnings per Share		 - $2.49 $1.30 $0.89 $0.67 $0.47 $0.45 $0.31 $0.25 $0.25
Weighted Average Basic Shares Outstanding		 4.47M 4.49M 7.96M 12.15M 18.42M 26.13M 28.81M 29.01M 37.65M 46.19M
Diluted Earnings per Share		 $0.78 $2.49 $1.31 $0.89 $0.67 $0.47 $0.45 $0.31 $0.25 $0.25
Weighted Average Diluted Shares Outstanding		 6.76M 4.49M 7.98M 12.15M 18.42M 26.13M 28.81M 29.01M 37.65M 46.19M
Weighted Average Basic & Diluted Shares Outstanding		 - - 11.46M 18.20M 18.42M 26.13M 28.81M 35.48M 45.42M 46.62M

Quarterly Income Statements for Entera Bio

This table shows Entera Bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.00 -2.02 -2.15 -3.02 -2.36 -2.57 -2.66 -3.20 -3.02 -3.51 -7.31
Consolidated Net Income / (Loss)		 -2.00 -2.02 -2.15 -3.02 -2.36 -2.57 -2.66 -3.20 -3.02 -3.51 -7.31
Net Income / (Loss) Continuing Operations		 -2.00 -2.02 -2.15 -3.02 -2.36 -2.57 -2.66 -3.20 -3.02 -3.51 -7.31
Total Pre-Tax Income 		-2.00 -2.02 -2.15 -3.02 -2.34 -2.57 -2.66 -3.20 -3.02 -3.51 -7.31
Total Operating Income		 -1.96 -2.06 -2.17 -3.02 -2.34 -2.56 -2.67 -3.26 -3.04 -3.54 -4.56
Total Gross Profit		 - 0.00 0.01 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.06 0.04 0.08 0.04 0.00 0.00 - 0.00 0.00
Operating Revenue		 - 0.00 0.06 0.04 - 0.04 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.05 0.04 0.08 0.04 0.00 0.00 - 0.00 0.00
Operating Cost of Revenue		 - 0.00 0.05 0.04 - 0.04 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 1.94 2.06 2.17 3.02 2.34 2.56 2.67 3.26 3.04 3.54 4.56
Selling, General & Admin Expense		 0.97 1.33 1.09 1.54 1.14 1.44 1.15 1.61 1.32 1.29 1.36
Research & Development Expense		 1.00 0.74 1.09 1.48 1.20 1.12 1.52 1.64 1.72 2.25 3.20
Total Other Income / (Expense), net		 -0.03 0.05 0.02 0.00 -0.01 -0.00 0.01 0.06 0.03 0.03 -2.75
Other Income / (Expense), net		 -0.03 0.05 0.02 0.00 -0.01 -0.00 0.01 0.06 0.03 0.03 -2.75
Basic Earnings per Share		 $0.07 $0.05 $0.06 $0.08 $0.06 $0.06 $0.06 $0.07 $0.06 $0.07 $0.14
Weighted Average Basic Shares Outstanding		 29.01M 36.74M 37.09M 37.64M 37.65M 43.38M 46.84M 47.09M 46.19M 47.76M 50.45M
Diluted Earnings per Share		 $0.07 $0.05 $0.06 $0.08 $0.06 $0.06 $0.06 $0.07 $0.06 $0.07 $0.14
Weighted Average Diluted Shares Outstanding		 29.01M 36.74M 37.09M 37.64M 37.65M 43.38M 46.84M 47.09M 46.19M 47.76M 50.45M
Weighted Average Basic & Diluted Shares Outstanding		 35.48M 35.79M 36.32M 36.83M 45.42M 45.45M 45.66M 45.86M 46.62M 49.23M 173.14M

Annual Cash Flow Statements for Entera Bio

This table details how cash moves in and out of Entera Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 2.96 7.58 -4.24 7.68 -6.56 16 -13 -1.29 -2.35 6.20
Net Cash From Operating Activities		 -4.22 -4.38 -14 -4.98 -11 -9.06 -12 -7.31 -6.82 -7.37
Net Cash From Continuing Operating Activities		 -4.22 -4.38 -14 -4.98 -11 -9.06 -12 -7.31 -6.81 -7.37
Net Income / (Loss) Continuing Operations		 -1.20 -11 -10 -11 -11 -12 -13 -8.89 -9.54 -11
Consolidated Net Income / (Loss)		 -1.20 -11 -10 -11 -11 -12 -13 -8.89 -9.54 -11
Depreciation Expense		 0.04 0.04 0.05 0.24 0.06 0.05 0.06 0.06 0.05 0.03
Non-Cash Adjustments To Reconcile Net Income		 -3.43 5.85 -3.00 4.89 0.95 1.88 2.17 1.69 2.56 2.78
Changes in Operating Assets and Liabilities, net		 0.38 0.93 -0.51 0.70 -0.35 1.19 -1.66 -0.17 0.13 1.26
Net Cash From Investing Activities		 -0.04 -0.05 -0.07 -0.04 -0.05 -0.02 -0.10 -0.02 -0.00 -0.11
Net Cash From Continuing Investing Activities		 -0.04 -0.05 -0.07 -0.04 -0.05 -0.02 -0.10 -0.02 -0.00 -0.11
Purchase of Property, Plant & Equipment		 -0.04 -0.05 -0.07 -0.04 -0.05 -0.02 -0.05 -0.02 -0.00 -0.11
Net Cash From Financing Activities		 7.22 11 9.62 13 4.05 25 0.01 6.04 4.48 14
Net Cash From Continuing Financing Activities		 7.22 12 9.62 13 4.05 25 0.01 6.04 4.48 14
Repayment of Debt		 - - - - - - 0.00 -0.58 -0.32 -0.26
Issuance of Common Equity		 - - - - 3.19 22 0.00 6.62 3.96 6.25
Other Financing Activities, net		 - 0.00 0.00 0.14 0.07 3.58 0.01 0.00 0.84 7.72
Effect of Exchange Rate Changes		 - - - - - - - - 0.00 -0.04
Cash Interest Received		 - 0.00 0.00 0.08 - - 0.00 0.02 0.07 0.18

Quarterly Cash Flow Statements for Entera Bio

This table details how cash moves in and out of Entera Bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 3.41 -1.83 -0.12 -2.14 1.75 12 -1.71 -2.30 -1.72 -2.96 6.49
Net Cash From Operating Activities		 -2.62 -1.86 -1.34 -2.15 -1.47 -1.40 -1.63 -2.50 -1.83 -3.09 -3.46
Net Cash From Continuing Operating Activities		 -2.62 -1.86 -1.34 -2.14 -1.47 -1.40 -1.63 -2.49 -1.84 -3.10 -3.46
Net Income / (Loss) Continuing Operations		 -2.00 -2.02 -2.15 -3.02 -2.36 -2.57 -2.66 -3.20 -3.02 -3.51 -7.31
Consolidated Net Income / (Loss)		 -2.00 -2.02 -2.15 -3.02 -2.36 -2.57 -2.66 -3.20 -3.02 -3.51 -7.31
Depreciation Expense		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Non-Cash Adjustments To Reconcile Net Income		 0.34 0.46 0.59 0.94 0.57 0.60 0.53 0.91 0.74 0.67 3.51
Changes in Operating Assets and Liabilities, net		 -0.97 -0.31 0.21 -0.08 0.31 0.56 0.49 -0.21 0.43 -0.27 0.33
Net Cash From Investing Activities		 -0.01 0.00 - - -0.00 -0.01 -0.03 -0.04 -0.03 0.00 -0.00
Net Cash From Continuing Investing Activities		 -0.01 0.00 - - -0.00 -0.01 -0.03 -0.04 -0.03 0.00 -0.00
Purchase of Property, Plant & Equipment		 -0.01 0.00 - - -0.00 -0.01 -0.03 -0.04 -0.03 0.00 -0.00
Net Cash From Financing Activities		 6.03 0.03 1.22 0.01 3.22 13 -0.05 0.25 0.17 0.13 9.96
Net Cash From Continuing Financing Activities		 6.03 0.03 1.22 0.01 3.22 13 -0.05 0.25 0.17 0.13 9.96
Repurchase of Common Equity		 - 0.00 -0.02 - - -0.19 -0.08 -0.00 - 0.00 -0.17
Other Financing Activities, net		 - 0.03 0.62 0.01 0.18 7.34 0.02 0.18 0.17 0.13 0.13
Cash Interest Received		 0.02 0.04 0.03 0.00 0.00 0.00 0.06 0.07 0.05 0.04 0.07

Annual Balance Sheets for Entera Bio

This table presents Entera Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 13 13 17 9.72 26 13 12 9.39 16
Total Current Assets		 12 12 16 9.11 25 13 11 8.97 15
Cash & Equivalents		 12 7.51 15 8.59 25 12 11 8.66 7.11
Restricted Cash		 - - - - - - - 0.00 7.78
Prepaid Expenses		 - - - - - - - - 0.42
Plant, Property, & Equipment, net		 0.21 0.22 0.20 0.19 0.16 0.14 0.10 0.06 0.13
Total Noncurrent Assets		 0.65 0.65 0.61 0.42 0.50 0.14 0.41 0.36 0.56
Employee Benefit Assets		 - - - 0.05 0.05 0.01 0.01 0.01 0.01
Other Noncurrent Operating Assets		 - - - 0.37 0.24 0.09 0.39 0.36 0.56
Total Liabilities & Shareholders' Equity		 13 13 17 9.72 26 13 12 9.39 16
Total Liabilities		 45 3.23 4.78 2.21 3.42 1.37 1.38 1.31 2.89
Total Current Liabilities		 2.02 3.16 4.59 1.84 3.16 1.34 1.09 1.18 2.20
Accounts Payable		 1.42 1.56 1.70 0.16 0.17 0.02 0.08 0.13 0.45
Accrued Expenses		 - - - 1.33 2.80 1.23 0.87 0.87 1.53
Other Current Liabilities		 0.00 0.23 0.44 0.19 0.18 0.09 0.13 0.17 0.23
Total Noncurrent Liabilities		 43 0.07 0.19 0.37 0.26 0.03 0.29 0.13 0.69
Long-Term Debt		 - - - - - - - - 0.39
Noncurrent Employee Benefit Liabilities		 - - - 0.13 0.14 0.03 0.03 0.03 0.04
Other Noncurrent Operating Liabilities		 - - - 0.24 0.12 0.00 0.26 0.10 0.26
Commitments & Contingencies		 - - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -34 10 12 7.51 23 12 10 8.08 13
Total Preferred & Common Equity		 -34 10 12 7.51 23 12 10 8.08 13
Total Common Equity		 -32 10 12 7.51 23 12 10 8.08 13
Common Stock		 0.00 49 63 78 105 107 115 122 138
Retained Earnings		 -42 -52 -63 -70 -82 -95 -104 -114 -125
Accumulated Other Comprehensive Income / (Loss)		 - 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04

Quarterly Balance Sheets for Entera Bio

This table presents Entera Bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 8.57 10 10 7.74 22 20 17 13 19
Total Current Assets		 8.02 9.75 9.60 7.34 21 19 17 12 19
Cash & Equivalents		 7.59 9.19 9.06 6.92 13 11 8.57 4.14 11
Restricted Cash		 - - - - 8.00 8.02 8.03 7.79 7.12
Prepaid Expenses		 0.43 0.56 0.48 0.38 0.52 0.44 0.41 0.57 0.47
Plant, Property, & Equipment, net		 0.11 0.09 0.08 0.07 0.06 0.08 0.11 0.13 0.12
Total Noncurrent Assets		 0.44 0.40 0.36 0.34 0.33 0.28 0.29 0.51 0.46
Employee Benefit Assets		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Other Noncurrent Operating Assets		 0.42 0.38 0.34 0.32 0.32 0.27 0.28 0.50 0.46
Total Liabilities & Shareholders' Equity		 8.57 10 10 7.74 22 20 17 13 19
Total Liabilities		 2.33 1.38 1.50 1.29 2.22 2.41 2.17 2.44 12
Total Current Liabilities		 2.03 1.12 1.29 1.11 1.62 1.84 1.57 1.58 2.10
Short-Term Debt		 - - - - - - - - 0.20
Accounts Payable		 0.56 0.07 0.07 0.18 0.13 0.38 0.22 0.27 0.58
Accrued Expenses		 1.33 0.90 1.07 0.77 1.32 1.27 1.19 1.12 1.33
Total Noncurrent Liabilities		 0.30 0.26 0.21 0.18 0.60 0.57 0.60 0.87 10
Long-Term Debt		 - - - - 0.52 0.52 0.53 0.57 0.28
Noncurrent Employee Benefit Liabilities		 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.04 0.04
Other Noncurrent Operating Liabilities		 0.27 0.22 0.18 0.15 0.05 0.01 0.04 0.26 9.79
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 6.24 8.86 8.53 6.45 19 17 15 11 7.27
Total Preferred & Common Equity		 6.24 8.86 8.53 6.45 19 17 15 11 7.27
Total Common Equity		 6.24 8.86 8.53 6.45 19 17 15 11 7.27
Common Stock		 109 115 117 118 136 136 138 140 143
Retained Earnings		 -102 -106 -109 -112 -116 -119 -122 -129 -136
Accumulated Other Comprehensive Income / (Loss)		 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04

Annual Metrics And Ratios for Entera Bio

This table displays calculated financial ratios and metrics derived from Entera Bio's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 11,459,780.00 18,202,237.00 23,738,642.00 23,738,642.00 28,809,922.00 28,813,952.00 - 45,857,242.00
DEI Adjusted Shares Outstanding		 0.00 0.00 11,459,780.00 18,202,237.00 23,738,642.00 23,738,642.00 28,809,922.00 28,813,952.00 - 45,857,242.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.90 -0.59 -0.47 -0.51 -0.45 -0.31 - -0.25
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% -52.80% 54.66% 56.44% -76.53% -100.00% 0.00% -76.80%
EBITDA Growth		 0.00% -108.31% 5.54% -4.89% 1.48% -9.52% -5.55% 31.59% -7.69% -20.34%
EBIT Growth		 0.00% -107.77% 5.42% -6.57% 2.96% -9.38% -5.62% 31.50% -7.53% -20.07%
NOPAT Growth		 0.00% -111.35% 4.25% -5.46% 2.50% -9.39% -6.55% 31.70% -7.81% -20.28%
Net Income Growth		 0.00% -833.86% 7.98% -4.77% -3.90% -8.66% -7.25% 31.99% -7.33% -19.89%
EPS Growth		 0.00% 219.23% -47.39% -32.06% -24.72% -29.85% -4.26% -31.11% -19.35% 0.00%
Operating Cash Flow Growth		 0.00% -3.87% -214.16% 63.84% -112.20% 14.15% -37.91% 41.52% 6.73% -8.10%
Free Cash Flow Firm Growth		 0.00% 0.00% -40.68% 72.37% -149.30% 6.28% -48.93% 43.53% -10.04% -7.38%
Invested Capital Growth		 0.00% 0.00% 3,443.52% -127.78% -1.88% -114.87% 76.15% -14.05% 8.37% -139.48%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -52.98% -100.00% 82.83% -66.13%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.45% 10.95% -3.84% -6.30%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.40% 10.92% -3.80% -6.24%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.27% 11.05% -4.06% -6.51%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.53% 10.47% -3.96% -6.10%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11.76% -8.82% -3.85% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.85% -9.04% 14.43% -5.23%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.60% 7.79% -0.87%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,945.45% 53.08% -25.27% -65.16%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 11.02% 17.81% 34.68% 24.63% 0.00% 4.97% 0.00%
EBITDA Margin		 0.00% 0.00% -2,154.60% -4,788.14% -3,050.14% -2,135.38% -9,604.48% 0.00% -5,238.12% -27,164.29%
Operating Margin		 0.00% 0.00% -2,172.20% -4,853.39% -3,059.73% -2,139.58% -9,714.18% 0.00% -5,295.58% -27,450.00%
EBIT Margin		 0.00% 0.00% -2,165.40% -4,888.98% -3,067.40% -2,144.66% -9,652.24% 0.00% -5,263.54% -27,235.71%
Profit (Net Income) Margin		 0.00% 0.00% -2,060.80% -4,574.15% -3,072.88% -2,134.33% -9,754.48% 0.00% -5,271.27% -27,235.71%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.18% 99.52% 101.06% 100.33% 100.15% 100.00%
Interest Burden Percent		 21.76% 97.81% 95.17% 93.56% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -386.41% -580.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -405.52% -551.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 471.10% 482.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 32.50% 84.68% -97.98% -115.46% -81.04% -76.17% -80.30% -103.34% -108.01%
Cash Return on Invested Capital (CROIC)		 0.00% -14,903.89% -575.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -81.35% -76.81% -84.74% -68.59% -66.13% 0.00% -90.07% -90.13%
Return on Assets (ROA)		 0.00% 0.00% -77.42% -71.86% -84.89% -68.26% -66.84% 0.00% -90.20% -90.13%
Return on Common Equity (ROCE)		 0.00% 29.77% 74.61% -97.98% -115.46% -81.04% -76.17% -80.30% -103.34% -108.01%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 32.50% -101.86% -90.57% -149.35% -54.01% -111.20% -85.59% -118.08% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.76 -7.94 -7.60 -8.02 -7.82 -8.55 -9.11 -6.22 -6.71 -8.07
NOPAT Margin		 0.00% 0.00% -1,520.54% -3,397.37% -2,141.81% -1,497.71% -6,799.93% 0.00% -3,706.91% -19,215.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 18.85% 19.11% -28.82% -31.50% -21.71% -21.28% -22.85% -28.78% -29.10%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -59.92% -83.04% -59.81%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 88.98% 82.19% 65.32% 75.37% 0.00% 95.03% 100.00%
SG&A Expenses to Revenue		 0.00% 0.00% 568.60% 1,813.98% 1,329.04% 996.50% 5,412.69% 0.00% 2,814.92% 13,154.76%
R&D to Revenue		 0.00% 0.00% 1,703.60% 3,050.42% 1,748.49% 1,185.81% 4,364.18% 0.00% 2,485.64% 14,295.24%
Operating Expenses to Revenue		 0.00% 0.00% 2,272.20% 4,864.41% 3,077.53% 2,174.26% 9,776.87% 0.00% 5,300.55% 27,450.00%
Earnings before Interest and Taxes (EBIT)		 -5.51 -11 -11 -12 -11 -12 -13 -8.86 -9.53 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.48 -11 -11 -11 -11 -12 -13 -8.80 -9.48 -11
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 2.41 2.18 2.65 3.26 1.79 1.68 9.88 6.84
Price to Tangible Book Value (P/TBV)		 0.00 0.00 2.57 2.30 2.65 3.26 1.79 1.68 9.88 6.84
Price to Revenue (P/Rev)		 0.00 0.00 48.70 110.14 54.49 128.84 156.94 0.00 440.99 2,133.59
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 4.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 33.69 46.32 30.95 85.24 65.08 0.00 393.14 1,788.59
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.03
Long-Term Debt to Equity		 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.03
Financial Leverage		 0.00 -1.00 -1.16 -0.87 -1.11 -1.11 -1.08 -1.05 -1.07 -1.09
Leverage Ratio		 0.00 -0.39 -1.09 1.36 1.36 1.19 1.14 1.12 1.15 1.20
Compound Leverage Factor		 0.00 -0.38 -1.04 1.28 1.36 1.19 1.14 1.12 1.15 1.20
Debt to Total Capital		 0.00% 0.00% 0.00% 1.01% 0.00% 0.00% 0.00% 0.00% 0.00% 2.91%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 1.01% 0.00% 0.00% 0.00% 0.00% 0.00% 2.91%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 91.60% 100.00% 98.99% 100.00% 100.00% 100.00% 100.00% 100.00% 97.09%
Debt to EBITDA		 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 -0.03
Net Debt to EBITDA		 0.00 0.00 0.00 1.33 0.00 0.00 0.00 0.00 0.00 1.27
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 -0.03
Debt to NOPAT		 0.00 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 -0.05
Net Debt to NOPAT		 0.00 0.00 0.00 1.88 0.00 0.00 0.00 0.00 0.00 1.80
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 -0.05
Altman Z-Score		 0.00 -6.16 -2.74 -3.49 -7.59 7.95 -3.18 -6.30 17.24 6.24
Noncontrolling Interest Sharing Ratio		 0.00% 8.40% 11.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 6.15 3.94 3.41 4.95 8.01 9.58 10.32 7.63 6.94
Quick Ratio		 0.00 5.81 2.60 3.37 4.81 7.93 9.36 10.10 7.47 3.23
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -8.05 -11 -3.13 -7.80 -7.31 -11 -6.15 -6.76 -7.26
Operating Cash Flow to CapEx		 -10,285.37% -8,588.24% -20,235.29% -12,437.50% -19,918.87% -53,311.76% -26,593.62% -43,000.00% -227,266.67% -6,887.85%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.04 0.02 0.03 0.03 0.01 0.00 0.02 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.47 1.37 2.61 0.62 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 2.32 1.11 1.85 3.28 0.91 0.00 2.31 0.44
Accounts Payable Turnover		 0.00 0.00 0.00 0.13 0.32 2.26 1.10 0.00 1.60 0.14
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 775.63 266.50 139.99 584.27 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 2,839.18 1,136.37 161.46 330.67 0.00 228.13 2,520.24
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 -2,063.55 -869.87 -21.47 253.60 0.00 -228.13 -2,520.24
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 0.11 3.83 -1.06 -1.08 -2.33 -0.56 -0.63 -0.58 -1.39
Invested Capital Turnover		 0.00 0.00 0.25 0.17 -0.34 -0.33 -0.09 0.00 -0.30 -0.04
Increase / (Decrease) in Invested Capital		 0.00 0.11 3.72 -4.89 -0.02 -1.24 1.77 -0.08 0.05 -0.81
Enterprise Value (EV)		 0.00 -0.55 17 11 11 49 8.72 6.39 71 75
Market Capitalization		 11 11 24 26 20 74 21 17 80 90
Book Value per Share		 $0.00 ($7.03) $1.27 $1.04 $0.41 $0.95 $0.41 $0.36 $0.22 $0.29
Tangible Book Value per Share		 $0.00 ($7.17) $1.19 $0.99 $0.41 $0.95 $0.41 $0.36 $0.22 $0.29
Total Capital		 0.00 -34 10 12 7.51 23 12 10 8.08 13
Total Debt		 0.00 0.00 0.00 0.12 0.00 0.00 0.00 0.00 0.00 0.39
Total Long-Term Debt		 0.00 0.00 0.00 0.12 0.00 0.00 0.00 0.00 0.00 0.39
Net Debt		 0.00 -12 -7.51 -15 -8.59 -25 -12 -11 -8.66 -14
Capital Expenditures (CapEx)		 0.04 0.05 0.07 0.04 0.05 0.02 0.05 0.02 0.00 0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -1.35 1.80 -4.14 -1.33 -2.72 -0.80 -0.85 -0.86 -1.79
Debt-free Net Working Capital (DFNWC)		 0.00 10 9.31 11 7.27 22 12 10 7.80 13
Net Working Capital (NWC)		 0.00 10 9.31 11 7.27 22 12 10 7.80 13
Net Nonoperating Expense (NNE)		 -2.56 3.26 2.70 2.78 3.40 3.64 3.96 2.67 2.83 3.37
Net Nonoperating Obligations (NNO)		 0.00 35 -6.29 -13 -8.59 -25 -12 -11 -8.66 -14
Total Depreciation and Amortization (D&A)		 0.04 0.04 0.05 0.24 0.06 0.05 0.06 0.06 0.05 0.03
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 360.00% -1,754.66% -363.01% -477.06% -597.76% 0.00% -477.35% -4,257.14%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 1,861.20% 4,679.66% 1,991.23% 3,882.31% 8,588.06% 0.00% 4,307.18% 31,178.57%
Net Working Capital to Revenue		 0.00% 0.00% 1,861.20% 4,679.66% 1,991.23% 3,882.31% 8,588.06% 0.00% 4,307.18% 31,178.57%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $1.30 $0.89 $0.54 $0.47 $0.45 $0.31 $0.25 $0.25
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 7.96M 12.15M 18.42M 28.80M 28.81M 29.01M 37.65M 46.19M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $1.31 $0.89 $0.55 $0.47 $0.45 $0.31 $0.25 $0.25
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 7.98M 12.15M 18.56M 28.80M 28.81M 29.01M 37.65M 46.19M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.47 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 11.46M 18.20M 23.74M 26.13M 28.81M 35.48M 45.42M 46.62M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.76 -7.94 -7.60 -8.02 -7.82 -8.55 -9.11 -6.22 -6.71 -8.07
Normalized NOPAT Margin		 0.00% 0.00% -1,520.54% -3,397.37% -2,141.81% -1,497.71% -6,799.93% 0.00% -3,706.91% -19,215.00%
Pre Tax Income Margin		 0.00% 0.00% -2,060.80% -4,574.15% -3,067.40% -2,144.66% -9,652.24% 0.00% -5,263.54% -27,235.71%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Entera Bio

This table displays calculated financial ratios and metrics derived from Entera Bio's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 28,813,952.00 35,481,341.00 35,785,309.00 36,324,579.00 - 45,420,676.00 45,452,167.00 45,663,381.00 45,857,242.00 46,622,239.00 49,225,321.00
DEI Adjusted Shares Outstanding		 28,813,952.00 35,481,341.00 35,785,309.00 36,324,579.00 - 45,420,676.00 45,452,167.00 45,663,381.00 45,857,242.00 46,622,239.00 49,225,321.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.07 -0.06 -0.06 -0.08 - -0.06 -0.06 -0.07 -0.07 -0.08 -0.15
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% -100.00% 0.00% -100.00% 0.00%
EBITDA Growth		 35.33% 7.90% 7.62% -28.85% -17.71% -27.69% -24.13% -6.05% -28.98% -36.69% -175.69%
EBIT Growth		 35.25% 7.90% 7.74% -28.55% -17.49% -27.27% -23.82% -5.93% -28.67% -36.54% -175.30%
NOPAT Growth		 36.02% 6.78% 7.08% -26.61% -19.05% -24.30% -23.23% -7.78% -30.17% -38.08% -71.03%
Net Income Growth		 34.27% 7.90% 7.74% -26.99% -18.20% -27.27% -23.82% -5.93% -27.91% -36.54% -175.30%
EPS Growth		 -30.00% -37.50% -25.00% 0.00% -14.29% 20.00% 0.00% -12.50% 0.00% 16.67% 133.33%
Operating Cash Flow Growth		 -30.13% -15.72% 14.37% -41.25% 43.94% 24.60% -22.17% -16.16% -24.95% -120.09% -112.39%
Free Cash Flow Firm Growth		 66.93% -32.81% -156.71% -803.28% -30.31% 16.62% 31.45% 36.64% 21.82% -72.32% 592.45%
Invested Capital Growth		 -14.05% 46.64% 41.97% 65.68% 8.37% -108.28% -108.59% -81.64% -139.48% 0.88% -877.31%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -26.32% 95.24% -48.78% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 15.15% -1.11% -6.49% -41.05% 22.49% -9.69% -3.52% -20.50% 5.73% -16.25% -108.78%
EBIT Q/Q Growth		 15.11% -1.10% -6.35% -40.84% 22.41% -9.51% -3.47% -20.48% 5.75% -16.21% -108.62%
NOPAT Q/Q Growth		 17.73% -5.04% -5.00% -39.54% 22.64% -9.67% -4.10% -22.04% 6.57% -16.34% -28.93%
Net Income Q/Q Growth		 16.14% -1.10% -6.35% -40.84% 21.95% -8.86% -3.47% -20.48% 5.75% -16.21% -108.62%
EPS Q/Q Growth		 -12.50% -28.57% 20.00% 33.33% -25.00% 0.00% 0.00% 16.67% -14.29% 16.67% 100.00%
Operating Cash Flow Q/Q Growth		 -71.61% 28.85% 28.30% -61.35% 31.89% 4.29% -16.17% -53.40% 26.74% -68.58% -12.10%
Free Cash Flow Firm Q/Q Growth		 -290.16% -33.35% -9.61% -58.39% 43.72% 14.67% 9.89% -46.40% 30.55% -88.07% 357.52%
Invested Capital Q/Q Growth		 53.08% 48.50% -60.74% 11.64% -25.27% -17.07% -60.97% 23.06% -65.16% 51.55% -1,487.22%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 15.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% -3,743.86% -7,166.67% -2,845.12% -6,092.86% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% -3,798.25% -7,192.86% -2,850.00% -6,102.38% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% -3,763.16% -7,192.86% -2,858.54% -6,111.90% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% -3,763.16% -7,192.86% -2,875.61% -6,111.90% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.60% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -80.30% -92.02% -101.84% -144.67% -103.34% -71.46% -82.22% -99.43% -108.01% -82.33% -138.92%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -20.95% -87.34% -48.91% -85.62% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% -20.95% -87.34% -49.21% -85.62% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -80.30% -92.02% -101.84% -144.67% -103.34% -71.46% -82.22% -99.43% -108.01% -82.33% -138.92%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -98.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.37 -1.44 -1.52 -2.11 -1.64 -1.79 -1.87 -2.28 -2.13 -2.48 -3.19
NOPAT Margin		 0.00% 0.00% -2,658.77% -5,035.00% -1,995.00% -4,271.67% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.32% -5.77% -6.92% -12.50% -7.34% -5.29% -5.75% -8.01% -7.66% -6.54% -22.69%
Return On Investment Capital (ROIC_SIMPLE)		 -13.23% -16.29% -17.76% -32.78% -20.25% -9.02% -10.50% -14.46% -15.78% -22.01% -41.22%
Cost of Revenue to Revenue		 0.00% 0.00% 84.21% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 1,908.77% 3,676.19% 1,385.37% 3,428.57% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 1,905.26% 3,516.67% 1,464.63% 2,673.81% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 3,814.04% 7,192.86% 2,850.00% 6,102.38% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.00 -2.02 -2.15 -3.02 -2.34 -2.57 -2.66 -3.20 -3.02 -3.51 -7.31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.98 -2.00 -2.13 -3.01 -2.33 -2.56 -2.65 -3.19 -3.01 -3.50 -7.30
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.68 6.92 8.00 11.09 9.88 3.81 5.16 5.93 6.84 4.96 12.29
Price to Tangible Book Value (P/TBV)		 1.68 6.92 8.00 11.09 9.88 3.81 5.16 5.93 6.84 4.96 12.29
Price to Revenue (P/Rev)		 0.00 0.00 1,197.30 722.47 440.99 330.68 536.08 729.13 2,133.59 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 1,038.42 652.62 393.14 240.73 425.55 599.50 1,788.59 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.03 0.03 0.03 0.03 0.05 0.07
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.03 0.03 0.03 0.03 0.05 0.04
Financial Leverage		 -1.05 -1.05 -1.09 -1.14 -1.07 -1.04 -1.06 -1.06 -1.09 -1.05 -1.48
Leverage Ratio		 1.12 1.15 1.22 1.29 1.15 1.13 1.15 1.16 1.20 1.16 1.60
Compound Leverage Factor		 1.12 1.15 1.22 1.29 1.15 1.13 1.15 1.16 1.20 1.16 1.60
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 2.59% 2.95% 3.34% 2.91% 5.04% 6.23%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.57%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 2.59% 2.95% 3.34% 2.91% 5.04% 3.67%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 97.41% 97.05% 96.66% 97.09% 94.96% 93.77%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.05 -0.05 -0.05 -0.03 -0.05 -0.03
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 2.00 1.74 1.50 1.27 0.92 1.06
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.05 -0.05 -0.05 -0.03 -0.05 -0.02
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.07 -0.07 -0.07 -0.05 -0.06 -0.05
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 2.84 2.48 2.12 1.80 1.30 1.78
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.07 -0.07 -0.07 -0.05 -0.06 -0.03
Altman Z-Score		 -4.37 12.56 12.39 12.81 19.76 13.08 14.29 15.59 7.98 -0.60 -5.60
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 10.32 8.70 7.42 6.61 7.63 13.07 10.47 10.83 6.94 7.93 8.98
Quick Ratio		 10.10 8.20 7.04 6.26 7.47 7.82 5.89 5.46 3.23 2.63 5.38
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.30 -1.73 -1.89 -3.00 -1.69 -1.44 -1.30 -1.90 -1.32 -2.48 6.39
Operating Cash Flow to CapEx		 -52,340.00% 0.00% 0.00% 0.00% -48,900.00% -17,550.00% -5,624.14% -5,818.60% -6,788.89% 0.00% -115,466.67%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.01 0.01 0.02 0.01 0.01 0.01 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 1.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.58 1.14 2.31 3.10 2.14 1.39 0.44 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.31 0.24 1.60 2.14 0.73 0.62 0.14 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 275.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 1,174.84 1,516.78 228.13 170.56 496.93 588.71 2,520.24 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 -899.49 -1,516.78 -228.13 -170.56 -496.93 -588.71 -2,520.24 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.63 -0.33 -0.52 -0.46 -0.58 -0.68 -1.09 -0.84 -1.39 -0.67 -11
Invested Capital Turnover		 0.00 0.00 -0.08 -0.11 -0.30 -0.44 -0.21 -0.19 -0.04 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.08 0.29 0.38 0.89 0.05 -0.35 -0.57 -0.38 -0.81 0.01 -9.59
Enterprise Value (EV)		 6.39 52 59 65 71 54 71 74 75 42 71
Market Capitalization		 17 61 68 72 80 74 89 90 90 53 89
Book Value per Share		 $0.36 $0.25 $0.24 $0.18 $0.22 $0.43 $0.38 $0.33 $0.29 $0.23 $0.15
Tangible Book Value per Share		 $0.36 $0.25 $0.24 $0.18 $0.22 $0.43 $0.38 $0.33 $0.29 $0.23 $0.15
Total Capital		 10 8.86 8.53 6.45 8.08 20 18 16 13 11 7.75
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.52 0.52 0.53 0.39 0.57 0.48
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.52 0.52 0.53 0.39 0.57 0.28
Net Debt		 -11 -9.19 -9.06 -6.92 -8.66 -20 -18 -16 -14 -11 -18
Capital Expenditures (CapEx)		 0.01 0.00 0.00 0.00 0.00 0.01 0.03 0.04 0.03 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.85 -0.56 -0.76 -0.69 -0.86 -0.98 -1.41 -1.17 -1.79 -1.01 -1.44
Debt-free Net Working Capital (DFNWC)		 10 8.63 8.30 6.23 7.80 20 17 15 13 11 17
Net Working Capital (NWC)		 10 8.63 8.30 6.23 7.80 20 17 15 13 11 17
Net Nonoperating Expense (NNE)		 0.62 0.57 0.63 0.91 0.72 0.77 0.79 0.92 0.89 1.03 4.12
Net Nonoperating Obligations (NNO)		 -11 -9.19 -9.06 -6.92 -8.66 -20 -18 -16 -14 -11 -18
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -1,324.56% -692.93% -477.35% -438.57% -846.99% -940.32% -4,257.14% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 14,563.16% 6,291.92% 4,307.18% 8,787.00% 10,522.29% 12,448.39% 31,178.57% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 14,563.16% 6,291.92% 4,307.18% 8,787.00% 10,522.29% 12,448.39% 31,178.57% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.07 $0.05 $0.06 $0.08 $0.06 $0.06 $0.06 $0.07 $0.06 $0.07 $0.14
Adjusted Weighted Average Basic Shares Outstanding		 29.01M 36.74M 37.09M 37.64M 37.65M 43.38M 46.84M 47.09M 46.19M 47.76M 50.45M
Adjusted Diluted Earnings per Share		 $0.07 $0.05 $0.06 $0.08 $0.06 $0.06 $0.06 $0.07 $0.06 $0.07 $0.14
Adjusted Weighted Average Diluted Shares Outstanding		 29.01M 36.74M 37.09M 37.64M 37.65M 43.38M 46.84M 47.09M 46.19M 47.76M 50.45M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 35.48M 35.79M 36.32M 36.83M 45.42M 45.45M 45.66M 45.86M 46.62M 49.23M 173.14M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.37 -1.44 -1.52 -2.11 -1.64 -1.79 -1.87 -2.28 -2.13 -2.48 -3.19
Normalized NOPAT Margin		 0.00% 0.00% -2,658.77% -5,035.00% -1,995.00% -4,271.67% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% -3,763.16% -7,192.86% -2,858.54% -6,111.90% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Entera Bio’s financial statements show a development-stage biotechnology company with no meaningful recurring revenue, rising research spending and continued reliance on external financing. The second quarter of 2026 included a substantial financing inflow that temporarily improved liquidity, but operating cash usage and accumulated losses remain significant risks.

  • Liquidity improved in Q2 2026. Cash and equivalents increased to $11.3 million from $4.1 million in Q1, while restricted cash totaled $7.1 million. The company reported $18.9 million in current assets against $2.1 million in current liabilities, although the availability of restricted cash may be limited.
  • Q2 financing provided a meaningful cash boost. Net cash from financing activities was $10.0 million, helping produce a $6.5 million increase in cash during the quarter despite a $3.5 million operating cash outflow.
  • Capital spending remains minimal. Purchases of property, plant and equipment were only $3,000 in Q2 2026, limiting the amount of cash required for physical infrastructure and equipment.
  • Debt remains relatively modest compared with current assets. Reported short- and long-term debt totaled approximately $483,000 in Q2 2026, although total liabilities increased sharply because of other noncurrent operating liabilities.

The company’s cash position has been supported primarily by equity and other financing rather than internally generated funds. Based on Q2’s $3.5 million operating cash burn, the combined cash and restricted cash balance of $18.2 million represents roughly five quarters of coverage before considering financing needs, restrictions on cash and changes in spending.

  • Entera Bio remains pre-revenue for practical purposes. Reported revenue was zero in Q2 2026 and Q1 2026, following only $42,000 in Q1 2025 and $57,000 in Q2 2024. Investors should focus on clinical progress and potential future commercialization rather than current sales trends.
  • Q2 2026 included a large noncash adjustment. The company reported $3.5 million of noncash adjustments, which reduced the gap between its $7.3 million net loss and its $3.5 million operating cash outflow. This means reported earnings and cash burn should be evaluated separately.
  • The financial data contains an earnings-per-share presentation inconsistency. Entera Bio reported a $7.3 million net loss attributable to common shareholders, but the standardized basic and diluted EPS fields show a positive $0.14. The loss figures are more consistent with a negative EPS, so investors should verify the company’s original filing before relying on the standardized EPS data.
  • Operating losses are widening. Q2 2026 operating expenses rose to $4.6 million from $3.5 million in Q1 2026 and $3.0 million in Q4 2025. The quarterly net loss expanded to $7.3 million from $3.5 million in Q1, partly because of $2.7 million in net other expense.
  • Research and development spending is increasing. R&D expense climbed to $3.2 million in Q2 2026 from $2.3 million in Q1 and $1.7 million in Q4 2025. This spending may support pipeline development, but it is also increasing the company’s near-term funding requirements.
  • Operating cash burn has accelerated. Quarterly operating cash outflows increased from $1.3 million in Q2 2024 to $2.5 million in Q3 2025, $3.1 million in Q1 2026 and $3.5 million in Q2 2026. Continued acceleration could shorten the company’s cash runway.
  • Entera Bio remains dependent on financing. Financing supplied $13.3 million in Q1 2025 and $10.0 million in Q2 2026, while operations consistently consumed cash. Future equity raises or other financing could be necessary if clinical spending remains elevated.
  • Share dilution has been substantial. Weighted-average basic shares increased from approximately 29.0 million in Q4 2023 to 50.5 million in Q2 2026. Additional capital raises could further dilute existing shareholders.
  • Shareholders’ equity has deteriorated recently. Total equity fell from $15.2 million in Q3 2025 to $10.7 million in Q1 2026 and $7.3 million in Q2 2026, reflecting continuing losses and other balance-sheet changes.
  • Total liabilities surged in Q2 2026. Liabilities rose to $12.2 million from $2.4 million in Q1, primarily because other noncurrent operating liabilities increased to $9.8 million from $263,000. Investors should review the underlying nature and terms of this liability before treating the improved cash position as fully available liquidity.
  • Accumulated losses remain very large. Retained earnings were negative $136.2 million in Q2 2026, compared with negative $119.2 million in Q2 2025, underscoring the company’s long history of losses and lack of operating profitability.

Overall, Entera Bio’s near-term financial position improved because of Q2 financing, but the underlying trend remains high risk. The company continues to burn cash, generate little or no revenue, increase R&D spending and rely on capital markets. The most important items for investors to monitor are clinical milestones, the composition of the $9.8 million in other noncurrent liabilities, quarterly cash burn and whether future financing can be secured without substantial additional dilution.

10/14/26 02:10 PM ETAI Generated. May Contain Errors.

Entera Bio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Entera Bio's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Entera Bio's net income appears to be on a downward trend, with a most recent value of -$11.44 million in 2025, falling from -$1.20 million in 2016. The previous period was -$9.54 million in 2024. View Entera Bio's forecast to see where analysts expect Entera Bio to go next.

Entera Bio's total operating income in 2025 was -$11.53 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $11.53 million

Over the last 9 years, Entera Bio's total revenue changed from $0.00 in 2016 to $42 thousand in 2025, a change of 4,200,000.0%.

In the past 11 quarters, Entera Bio's cash and equivalents has ranged from $4.14 million in Q1 2026 to $12.57 million in Q1 2025, and is currently $11.31 million as of their latest financial filing in Q2 2026.

Entera Bio had total debt of $393 thousand at the end of 2025, compared with none in 2024, and none in 2016.

Over the last 9 years, Entera Bio's book value per share changed from 0.00 in 2016 to 0.29 in 2025, a change of 28.6%.


Related Companies

Financial statements for NASDAQ:ENTX last updated on 8/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...
Paradigm Press | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
Why Some AI Stocks Already Surged Over 300 Percent
Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...
Brownstone Research | Sponsoredtc pixel
My next big call (under $1)
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Did you grab your copy yet?
Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...
Profits Run | Sponsoredtc pixel
Trump To Relaunch USD?
President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may b...
Porter & Company | Sponsoredtc pixel